Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for ovarian cancer, susceptibility to, 1 has been reported in the published literature.
No clinical trials have been registered for ovarian cancer, susceptibility to, 1.
246 publications have been identified in PubMed for ovarian cancer, susceptibility to, 1. Kisho has analyzed 177 by research type. Research spans Epidemiology / Natural History (32%), Basic Science / Preclinical (25%), and Review / Meta-Analysis (24%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 56 | 32% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:37 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
Laboratory research |
44 |
25% |
Research summaries | 43 | 24% |
Testing and diagnosis research | 21 | 12% |
New treatment approaches | 6 | 3% |
Clinical study results | 5 | 3% |
Other research | 1 | 1% |
Patient case studies | 1 | 1% |
Krückel A (2026). [PMID: 41528496](https://pubmed.ncbi.nlm.nih.gov/41528496/). *Arch Gynecol Obstet*. [Review / Meta-Analysis]
Larsen RK 4th (2026). [PMID: 41027427](https://pubmed.ncbi.nlm.nih.gov/41027427/). *Dev Cell*. [Epidemiology / Natural History]
Jurgiel WA (2026). [PMID: 41538105](https://pubmed.ncbi.nlm.nih.gov/41538105/). *Discov Oncol*. [Review / Meta-Analysis]
Garofalo C (2026). [PMID: 41761980](https://pubmed.ncbi.nlm.nih.gov/41761980/). *Front Biosci (Landmark Ed)*. [Basic Science / Preclinical]
Campoy S (2026). [PMID: 41389835](https://pubmed.ncbi.nlm.nih.gov/41389835/). *J Natl Cancer Inst*. [Review / Meta-Analysis]
Zhang Z (2026). [PMID: 41201259](https://pubmed.ncbi.nlm.nih.gov/41201259/). *Cancer Epidemiol Biomarkers Prev*. [Epidemiology / Natural History]
Zamani N (2026). [PMID: 42118082](https://pubmed.ncbi.nlm.nih.gov/42118082/). *Genet Med*. [Epidemiology / Natural History]
Kumar R (2026). [PMID: 33232028](https://pubmed.ncbi.nlm.nih.gov/33232028/). *Unknown Journal*. [Epidemiology / Natural History]
Qiu T (2026). [PMID: 41480895](https://pubmed.ncbi.nlm.nih.gov/41480895/). *J Am Chem Soc*. [Gene Therapy / Novel Therapeutics]
Mao J (2026). [PMID: 41771775](https://pubmed.ncbi.nlm.nih.gov/41771775/). *Technol Cancer Res Treat*. [Review / Meta-Analysis]